TMDI VS CYTO Stock Comparison

Performance

TMDI
10/100

TMDI returned -73.08% in the last 12 months. Based on the other stocks in it's sector with an average return of -23.10%, it's performance is below average giving it a grade of 10 of 100.

CYTO
10/100

CYTO returned -98.21% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

TMDI
65/100

TMDI had a bullish sentiment score of 64.63% across Twitter and StockTwits over the last 12 months. It had an average of 17.43 posts, 15.89 comments, and 57.00 likes per day.

CYTO

"Sentiment" not found for CYTO

Technicals

TMDI
14/100

TMDI receieves a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

CYTO
14/100

CYTO receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

TMDI
16/100

TMDI has missed earnings 3 times in the last 20 quarters.

CYTO
44/100

CYTO has missed earnings 2 times in the last 20 quarters.

Volatility

TMDI
55/100

TMDI has had a higher than average amount of volatility over the last 12 months giving it a grade of 54 of 100.

CYTO
25/100

CYTO has had a lower than average amount of volatility over the last 12 months giving it a score of 25 of 100.

Profit

TMDI

"Profit" not found for TMDI

CYTO
13/100

Out of the last 20 quarters, CYTO has had 2 profitable quarters and has increased their profits year over year on 2 of them.

All score calculations are broken down here to help you make more informed investing decisions

Titan Medical Inc. Ordinary Shares Summary

Nasdaq / TMDI

Healthcare

Medical Devices

Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.

Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) Summary

Nasdaq / CYTO

Healthcare

Biotechnology

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Power up your portfolio